Home › Clear-cell metastatic renal cell carcinoma › Tennessee
Clear-cell metastatic renal cell carcinoma clinical trials in Tennessee
6 studies for Clear-cell metastatic renal cell carcinoma are looking for participants at sites in Tennessee.
Cities in Tennessee
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Research Site, Nashville
- Research Site, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07011719Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT07748988Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Tennessee Oncology, PLLC- Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Memorial, Chattanooga
- and 22 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07227415Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05361720A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07195682Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT07383441From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.